Treg Directed Therapy for Autoimmune Disorders Summit 2018 Boston, Massachusetts, USA 22-24 May 2018

Description:
This is your first and only opportunity to listen to the most advanced clinical case studies from Nektar Therapeutics and Amgen which explore the use of IL-2 to enhance the expansion and activation of the Treg cells. Delve deeper with expert insights from Roche and ILTOO Pharma to understand how IL-2 at low doses could selectively stimulate Treg cells.

Identify yourself as a leader in this community and join the discussion exploring the challenges in translating a proof of concept in autoimmune therapies from animal models to clinic. This meeting will provide the platform for conversations to be had to accelerate the clinical translation of Treg directed therapies.

URLs:
Booking: https://go.evvnt.com/197029-0?pid=4440
Brochure: https://go.evvnt.com/197029-1?pid=4440
Inquiries: https://go.evvnt.com/197029-2?pid=4440

Prices:
Conference Only (Earlybird ends Feb 23): USD 1999,
Conference Only (Earlybird ends Mar 23): USD 2199,
Conference Only (Earlybird ends Apr 20): USD 2399,
Conference Only: USD 2799,
Conference Academic Only (Earlybird ends Feb 23): USD 1399,
Conference Academic Only (Earlybird ends Mar 23): USD 1599,
Conference Academic Only (Earlybird ends Apr 20): USD 1799,
Conference Academic Only: USD 1999,
Workshop Only: USD 499

Speakers: Chris Haqq, Kevin Gorski, Nadia Tchao, David Wraith, Andrew Scharenberg, Simrit Parmar, Robert Plenge, Stephen Miller, Todd Brusko, Jeremie Mariau, Laurence Turka, Jason Fontenot, Leonard Dragone, Jonathan Zalevsky, Aaron Winkler, David Klatzmann, Jonathan Esensten, Leslie Kean

Time: 8:00 am to 4:00 pm